SPOTLIGHT: Daclizumab delivers positive data

A mid-stage trial for the humanized monoclonal antibody daclizumab--which is being developed by Biogen Idec and PDL--hit its primary endpoint for multiple sclerosis. Patients saw a significant reduction in new or enlarged gadolinium-contrast-enhancing lesions at week 24. Release